Vildagliptin

维格列汀

Report date: 2026/01/04 09:57:41
NME

Base Information

Drug NameVildagliptin
Drug Alias Namevildagliptina维达列汀维达利停vildagliptine维达格列汀 +[16] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDipeptidyl peptidase IV inhibitors
TargetsDipeptidyl peptidase IV
Therapy Area/IndicationsSchizophreniaDyslipidemiasInsulin Resistance +[9] 
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaDiabetes Mellitus, Type 2
Original Approved Country/TerritoryEU
Original Approved Date2007/09/25
Country/TerritoryBelgiumBulgariaCanada +[24] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesDr. Reddy's Laboratories LLCNovartis Pharma AgNovartis Europharm Ltd +[4] 
Inactive CompaniesFederal University Of Sao PauloGenuine Research Center, EgyptUT Health San Antonio +[7] 
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsSchizophreniaDyslipidemiasInsulin Resistance +[8] 

Other Information

ATC CodeA10BH02
Related LinksWikipediaDrugBankKEGG